Biochemist: Ultra-low temperature storage of mRNA jabs makes unstable product even more unstable

As has been discussed in a different video (linked below), the mRNA jab fluid is unstable, which means is may be no longer homogeneous. A consequence is that some people may be injected with a much larger dose than intended, causing a severe and possibly lethal reaction.

Pfizer is well aware of this problem, and tried to it by having the products stored at ultra-low temperatures of -72°C until shortly before injection. However, the severe temperature shock of 109°C when thawing to room temperature and then to body temperature (from -72°C to +37°C) likely makes the fluid even more unstable.

After thawing to room temperature, the fluid is diluted with sodium chloride which makes the product even more unstable. BioNTech even admits in the patent that it was awarded in November of 2019.

RELATED VIDEOS

Biochemist explains: Individual mRNA jab doses can vary enormously due to unstable fluid
https://rumble.com/v3vowg4

2019 BioNTech patent admits: mRNA jabs unsuitable as pharmaceutical product because toxic, unstable
https://rumble.com/v3vp51a

REFERENCES

RNA Formulation for Immunotherapy. US Patent 10,485,884
https://patentimages.storage.googleapis.com/de/67/95/27ec2ea27a32d9/US10485884.pdf

Scientific article by Gabriele Segalla:

Chemical-Physical Criticality and Toxicological Potential of Lipid Nanomaterials Contained in a COVID-19 mRNA Vaccine (Jan 26, 2023) | International Journal of Vaccine Theory, Practice, and Research (IJVTPR)
https://ijvtpr.com/index.php/IJVTPR/article/view/68

SOURCE

Segment from:
https://odysee.com/@ICIC/WHO,-BioNTech-Pfizer-and-FDA-EMA-Knew-Everything-at-the-End-of-2019_FINAL_HD720